The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis hyperalgesia allodynia inflammatory hyperalgesia neuropathic hyperalgesia acute nociception osteoporosis multiple sclerosis-associated spasticity autoimmune disorders allergic reactions CNS inflammation atherosclerosis undesired immune cell activity and inflammation age-related macular degeneration cough leukemia lymphoma CNS tumors prostate cancer Alzheimers disease stroke-induced damage dementia amyotrophic lateral sclerosis, and Parkinsons disease.本発明はカンナビノイドCB2受容体の活性をモジュレートする特定の式Iaの化合物およびその医薬組成物に関する。本発明はさらにCB1受容体およびCB2受容体の両方の活性をモジュレートする特定の式Iaの化合物およびその医薬組成物に関する。本発明の化合物および医薬組成物は、疼痛、例えば、骨および関節疼痛、筋肉疼痛、歯痛、頭痛、炎症性疼痛、神経因性疼痛、治療の有害作用として生じる疼痛ならびに変形性関節症に随伴する疼痛;痛覚過敏;異痛症;炎症性痛覚過敏;神経障害性痛覚過敏;急性侵害受容;骨粗鬆症;多発性硬化症に関連する痙縮;自己免疫障害;アレルギー反応;CNS炎症;アテローム硬化症;望ましくない免疫細胞活性および炎症;加齢性黄斑変性;咳;白血病;リンパ腫;CNS腫瘍;前立腺癌;アルツハイマー病;卒中誘発損傷;認知症;筋萎縮性側索硬化症およびパーキンソン病を治療する際に有用な方法を対象とする。
